Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0TQSIC
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
WBP301088-X2
|
|||||
| Synonyms |
WBP301088-X2
Click to Show/Hide
|
|||||
| Organization |
DUALITY BIOLOGICS (SUZHOU) CO., LTD
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
5.68
|
|||||
| Structure |
|
|||||
| Antibody Name |
Anti-b7h3
|
Antibody Info | ||||
| Antigen Name |
CD276 antigen (CD276)
|
Antigen Info | ||||
| Payload Name |
Topo1 inhibitor F
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase I (TOP1)
|
Target Info | ||||
| Linker Name |
Mc-Gly-Gly-Phe-Gly
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
X2
|
|||||
General Information of The ADMET Data Related to This ADC(2027 Update)
Absorption
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Maximum Observed Concentration (Cmax) | 71.9 | ug/mL |
Blood was collected from the forelimb veins of cynomolgus monkeys in each group, and treated samples of the blood collected at 0 h before and 0.5 h, 1 h, 4 h, 8 h, 24 h, 48 h, 72 h, 96 h, 168 h, 240 h, 336 h, 504 h, and 672 h after the administration were used as PK samples.
Click to Show/Hide
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 2070 | h*ug/mL |
Blood was collected from the forelimb veins of cynomolgus monkeys in each group, and treated samples of the blood collected at 0 h before and 0.5 h, 1 h, 4 h, 8 h, 24 h, 48 h, 72 h, 96 h, 168 h, 240 h, 336 h, 504 h, and 672 h after the administration were used as PK samples.
Click to Show/Hide
|
[1] |
Distribution
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Area Under the Concentration-Time Curve (AUC) | 2070 | h*ug/mL |
Blood was collected from the forelimb veins of cynomolgus monkeys in each group, and treated samples of the blood collected at 0 h before and 0.5 h, 1 h, 4 h, 8 h, 24 h, 48 h, 72 h, 96 h, 168 h, 240 h, 336 h, 504 h, and 672 h after the administration were used as PK samples.
Click to Show/Hide
|
[1] |
Metabolism
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Area Under the Concentration-Time Curve (AUC) | 2070 | h*ug/mL |
Blood was collected from the forelimb veins of cynomolgus monkeys in each group, and treated samples of the blood collected at 0 h before and 0.5 h, 1 h, 4 h, 8 h, 24 h, 48 h, 72 h, 96 h, 168 h, 240 h, 336 h, 504 h, and 672 h after the administration were used as PK samples.
Click to Show/Hide
|
[1] |
Excretion
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Area Under the Concentration-Time Curve (AUC) | 2070 | h*ug/mL |
Blood was collected from the forelimb veins of cynomolgus monkeys in each group, and treated samples of the blood collected at 0 h before and 0.5 h, 1 h, 4 h, 8 h, 24 h, 48 h, 72 h, 96 h, 168 h, 240 h, 336 h, 504 h, and 672 h after the administration were used as PK samples.
Click to Show/Hide
|
[1] |
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 4.8 nM | Positive b7h3 expression (b7h3+++/++) | ||
| Method Description |
Anti-B7H3 ADC WBP301088-X2 was incubated with human tumor cells that positively expressed B7H3 for 7 days, and the inhibitory effect thereof on cell proliferation was assessed through a CellTiter-Glo@ chemiluminescence cell viability assay
|
||||
| In Vitro Model | Lung adenocarcinoma | NCI-H1568 cells | CVCL_1476 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 11.4 nM | Positive b7h3 expression (b7h3+++/++) | ||
| Method Description |
Anti-B7H3 ADC WBP301088-X2 was incubated with human tumor cells that positively expressed B7H3 for 7 days, and the inhibitory effect thereof on cell proliferation was assessed through a CellTiter-Glo@ chemiluminescence cell viability assay
|
||||
| In Vitro Model | Minimally invasive lung adenocarcinoma | NCI-H358 cells | CVCL_1559 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 52.3 nM | Positive b7h3 expression (b7h3+++/++) | ||
| Method Description |
Anti-B7H3 ADC WBP301088-X2 was incubated with human tumor cells that positively expressed B7H3 for 7 days, and the inhibitory effect thereof on cell proliferation was assessed through a CellTiter-Glo@ chemiluminescence cell viability assay
|
||||
| In Vitro Model | Lung adenocarcinoma | Calu-6 cells | CVCL_0236 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 55.5 nM | Positive b7h3 expression (b7h3+++/++) | ||
| Method Description |
Anti-B7H3 ADC WBP301088-X2 was incubated with human tumor cells that positively expressed B7H3 for 7 days, and the inhibitory effect thereof on cell proliferation was assessed through a CellTiter-Glo@ chemiluminescence cell viability assay
|
||||
| In Vitro Model | Invasive breast carcinoma | MCF-7 cells | CVCL_0031 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 86.5 nM | Positive b7h3 expression (b7h3+++/++) | ||
| Method Description |
Anti-B7H3 ADC WBP301088-X2 was incubated with human tumor cells that positively expressed B7H3 for 7 days, and the inhibitory effect thereof on cell proliferation was assessed through a CellTiter-Glo@ chemiluminescence cell viability assay
|
||||
| In Vitro Model | Glioblastoma | U87 MG cells | CVCL_0022 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 164.7 nM | Positive b7h3 expression (b7h3+++/++) | ||
| Method Description |
Anti-B7H3 ADC WBP301088-X2 was incubated with human tumor cells that positively expressed B7H3 for 7 days, and the inhibitory effect thereof on cell proliferation was assessed through a CellTiter-Glo@ chemiluminescence cell viability assay
|
||||
| In Vitro Model | Amelanotic melanoma | A375 cells | CVCL_0132 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 180.8 nM | Positive b7h3 expression (b7h3+++/++) | ||
| Method Description |
Anti-B7H3 ADC WBP301088-X2 was incubated with human tumor cells that positively expressed B7H3 for 7 days, and the inhibitory effect thereof on cell proliferation was assessed through a CellTiter-Glo@ chemiluminescence cell viability assay
|
||||
| In Vitro Model | Prostate carcinoma | PC-3 cells | CVCL_0035 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 268.8 nM | Positive b7h3 expression (b7h3+++/++) | ||
| Method Description |
Anti-B7H3 ADC WBP301088-X2 was incubated with human tumor cells that positively expressed B7H3 for 7 days, and the inhibitory effect thereof on cell proliferation was assessed through a CellTiter-Glo@ chemiluminescence cell viability assay
|
||||
| In Vitro Model | Breast carcinoma | CAL-120 cells | CVCL_1104 | ||
| Experiment 9 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 369.3 nM | Positive b7h3 expression (b7h3+++/++) | ||
| Method Description |
Anti-B7H3 ADC WBP301088-X2 was incubated with human tumor cells that positively expressed B7H3 for 7 days, and the inhibitory effect thereof on cell proliferation was assessed through a CellTiter-Glo@ chemiluminescence cell viability assay
|
||||
| In Vitro Model | Lung adenocarcinoma | A549 cells | CVCL_0023 | ||
| Experiment 10 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 446 nM | Positive b7h3 expression (b7h3+++/++) | ||
| Method Description |
Anti-B7H3 ADC WBP301088-X2 was incubated with human tumor cells that positively expressed B7H3 for 7 days, and the inhibitory effect thereof on cell proliferation was assessed through a CellTiter-Glo@ chemiluminescence cell viability assay
|
||||
| In Vitro Model | Colon adenocarcinoma | HT-29 cells | CVCL_0320 | ||